Articles tagged with Drug Studies
A new four-drug combination, DKRd, has emerged as a highly effective and safe treatment for newly diagnosed multiple myeloma patients. The ADVANCE clinical trial shows that 59% of patients treated with DKRd were MRD-negative after eight cycles of treatment, compared to 36% of KRd-treated patients.
The research aims to improve the survivability of wounded soldiers, enhance combat safety, and accelerate postoperative recovery in a multicenter pivotal clinical study. OYE's technology has shown promise in reducing mortality rates, lowering healthcare costs, and improving surgical workflow efficiency.
The ISSCR has assembled an international consortium to support the adoption of human stem cell-derived disease models for drug discovery and development. This initiative aims to reduce R&D costs and accelerate therapy development, aligning with efforts by regulatory bodies such as the FDA, NIH, and European Commission.
Researchers found that an inexpensive HIV drug can improve vision in patients with diabetic macular edema (DME) more effectively and at a lower cost than existing treatments. The drug, lamivudine, is taken orally and may represent a game-changing option for millions of patients worldwide.
A phase 3 trial announced today demonstrated lorundrostat's safety and effectiveness in reducing blood pressure in patients with resistant hypertension. The treatment, which blocks the production of aldosterone from the adrenal glands, achieved clinically meaningful and sustained reductions in systolic blood pressure.
The Center for Research Innovation in Biotechnology (CRIB) has developed a comprehensive database of active pharmaceutical ingredients with evidence of clinical testing. The database provides valuable information on drug discovery and development, including pricing, sponsors, and intended clinical applications.
Researchers found that denosumab increases tumour-infiltrating immune cells in early-stage breast cancer patients, particularly in type B luminal tumours. This increase is associated with a potential boost to the anti-tumor immune response and offers a valuable avenue for clinical interest.
A study reveals pharmacy care is perceived differently by diverse populations, with notable gaps in communication for patients with disabilities. The research highlights the importance of effective communication and accessible spaces for pharmacists to provide high-quality care.
A new head-to-head study has shown that tirzepatide results in around 50% more weight loss than semaglutide in adults with obesity. The study found that tirzepatide led to an average weight loss of 20.2%, significantly higher than the 13.7% achieved with semaglutide.
A real-world study of 1,752 patients with stage III or IV ovarian cancer found that adding bevacizumab to chemotherapy improved overall survival for those with advanced disease and residual cancer. Benefits were mostly seen in high-risk patients, not the general population.
A systematic review of available evidence found GLP-1 RAs lead to significant weight loss and improved blood sugar control in adults with severe mental illness. The analysis also showed that these medications were not associated with a worsening of mental state or suicidal behaviour.
Researchers found that patients taking HIV drugs called NRTIs are substantially less likely to develop Alzheimer's disease. The study, led by Jayakrishna Ambati, analyzed data from two large health insurance databases and determined a significant reduction in Alzheimer's risk among patients on NRTIs.
A clinical trial finds that moxidectin is more effective than current treatment ivermectin for lymphatic filariasis, a disease affecting millions in Africa. Moxidectin has a persistent effect and may require fewer rounds of treatment, potentially accelerating its elimination.
Rasika Dias, a renowned chemist at UTA, has been named a 2025 fellow of the Royal Society of Chemistry for his groundbreaking contributions to chemical sciences. He is the second chemistry faculty member to receive this honor.
A new gene therapy has successfully restored immune function in nine children with severe leukocyte adhesion deficiency-I (LAD-I), a rare genetic disorder. The treatment has eliminated symptoms and reduced severe infections, offering a life-changing benefit to these patients.
A Phase Ia/Ib trial found that zongertinib demonstrated clinical benefits for patients with advanced HER2-mutant non-small cell lung cancer, particularly those with specific HER2 mutations. The treatment showed a 71% objective response rate and manageable side effects.
A global research initiative analyzing data from nearly 2 million people in diverse populations worldwide has uncovered multiple new genes associated with osteoarthritis. The study also identified key genetic pathways and 69 genes whose protein products are targeted by approved drugs, paving the way for repurposed treatments.
The International Progressive MS Alliance has awarded €100,000 to three development project teams to plan clinical trials. The projects focus on developing new treatments for progressive MS, including exercise-induced fatigability, neural stem cell therapy, and salbutamol treatment.
A phase II trial found that pembrolizumab significantly reduced recurrence in patients with DNA mismatch repair-deficient early-stage solid cancers who had detectable circulating tumor DNA after surgery. The study suggests that using ctDNA to guide immunotherapy may help prevent relapse in high-risk patients.
A novel topical BRAF inhibitor gel called LUT014 has been shown to significantly reduce the severity of an acne-like rash in patients undergoing anti-EGFR therapies for colorectal cancer. The treatment's safety and effectiveness have been confirmed, offering a potential solution to managing this common side effect.
The treatment demonstrated early signals of efficacy, with 65.7% of patients experiencing lasting stable disease, and was generally well-tolerated, with most adverse events being mild and manageable.
A clinical trial found that LUT014, a topical BRAF inhibitor, significantly reduced the severity of acne-like skin rashes caused by targeted therapy for colorectal cancer. Patients who received LUT014 had improved quality of life and were able to continue receiving their cancer treatment with reduced side effects.
The study shows that Huo Xue Tong Luo capsule inhibits osteoclast formation and protects bone mass in ovariectomized mice. The PI3K-AKT signaling pathway is targeted to prevent bone loss induced by ovariectomy.
A study published in Food Chemistry: Molecular Sciences found that cinnamaldehyde in cinnamon activates receptors controlling medication clearance, raising concerns about potential interactions. Researchers recommend consulting a doctor before using cinnamon as a dietary supplement to avoid rapid clearance of prescription medicines.
Researchers identified a potential new treatment, lorundrostat, which reduced systolic blood pressure in individuals with uncontrolled or treatment-resistant hypertension. The study found a significant 15-point reduction in systolic blood pressure compared to placebo.
Researchers at Pennington Biomedical Research Center investigated tirzepatide's effects on weight loss and metabolic health. The study found that tirzepatide decreased calorie intake and increased fat oxidation, leading to significant weight loss. However, the drug did not decrease the slowing down of metabolic rate usually observed wi...
Researchers successfully treated atherosclerosis and fatty liver disease using DT-109 in nonhuman primates, which has potential as a dual therapy for two common conditions. The compound reduced the formation of atherosclerotic plaques and stopped critical processes that lead to vascular calcification.
This review compares the bioactive components and medicinal properties of natural and cultivated O. sinensis, highlighting differences in composition and effectiveness for specific therapeutic uses. Polysaccharides, nucleosides, sterols, and amino acids contribute to their health benefits, with natural specimens often exhibiting higher...
A new study reveals promising progress toward predicting how patients with major depressive disorder will respond to antidepressant medications. Brain connectivity patterns were found to significantly improve predictions of treatment response across two large, independent clinical trials.
Researchers developed an AI platform that tracks cancer biomarkers to personalize treatment dose adjustments for patients with advanced solid tumors. The study resulted in optimal doses being administered to 97.2% of patients, with average reductions of 20%.
A single dose of a psychedelic compound can enhance cognitive flexibility for weeks after administration, according to a groundbreaking study. Mice treated with the compound showed improved performance in reversal learning tasks compared to control groups when tested weeks later.
Researchers at Texas Tech University Health Sciences Center have received a $1.94 million grant to study inhibitors that target peripheral neuropathic pain. The project aims to develop novel non-opioid and non-addicting therapies capable of effectively managing chronic pain.
A new oral small molecule glucagon-like peptide-1 (GLP-1) receptor agonist, Orforglipron, has demonstrated significant weight loss of 7.9% in individuals with diabetes and impaired glycemic control. The safety and tolerability of the medication are consistent with injectable therapies, making it a potentially accessible treatment option.
Adding an experimental cancer drug to standard TB treatment reduces lung damage and prevents post-TB lung disease in mice. Researchers found that the drug doubled pulmonary apoptosis and reduced lung scarring by 40% compared to standard treatments.
A new study found that both oral and injectable forms of naltrexone are effective in reducing heavy drinking among hospitalized patients. The medication was administered before discharge, resulting in a significant decrease in heavy drinking within the last 30 days of the three-month follow-up period.
Researchers have identified a combination of drugs that prevents enteroviruses from replicating, which could lead to an effective treatment for global health problem. The combination includes pleconaril, AG7404, and mindeudesivir, which shows great potential for finding broad-spectrum treatment methods against enteroviruses.
Researchers investigated the neuroregenerative potential of 5-NOT and Epi, discovering they protected SH-SY5Y cells from MPP+ toxicity by regulating key proteins. The findings support 5-NOT as a glycomimetic drug candidate for Parkinson's disease treatment.
Researchers have initiated a clinical trial using an investigational medicine to lower amyloid precursor protein, targeting Alzheimer's disease in adults with Down syndrome. The study aims to prevent the development of Alzheimer's disease by addressing its underlying genetic cause.
A new study published in Brain Medicine found that administering Osanetant shortly after a traumatic event significantly dampens fear expression in female mice. This suggests that targeting fear memory at its roots may be an effective intervention to reduce PTSD-like behaviors.
A new Northwestern University study finds that NU-9 improves neuron health in animal models of Alzheimer's disease by addressing the underlying mechanisms of misfolded proteins. The drug reduces protein buildup and prevents inflammation, showing potential for treating neurodegenerative diseases.
A team of scientists at the University of Florida has developed a new drug compound that selectively targets delta opioid receptors, providing pain relief without the dangerous side effects associated with opioids. The study's findings offer a promising approach to developing safer pain treatments, which could also be applied to treati...
A Phase 3 trial found that ChemoID improves objective response rates, median progression-free survival, and duration of response in patients with recurrent platinum-resistant ovarian cancer. The test identifies effective treatments by challenging cancer stem cells against specific anticancer drugs.
The European HTA agencies and EMA have developed joint positions to address methodological challenges in assessing new drugs. Key findings include the need for randomized controlled trials and flexible study designs that can reduce sample size requirements and development timeframes.
The SUMMIT trial shows tirzepatide reduces the risk of cardiovascular death or worsening heart failure in patients with obesity, chronic kidney disease, and heart failure, while improving kidney function. Researchers found significant improvements in both patient groups with and without chronic kidney disease.
A new clinical trial found that oral semaglutide can significantly reduce cardiovascular events in people with type 2 diabetes and pre-existing cardiovascular disease. The medication decreased the risk of major cardiac events by 14% compared to placebo, with nonfatal myocardial infarction seeing the greatest reductions in risk.
A new antidote, bentracimab, safely restored platelet function in patients on ticagrelor, reducing the risk of bleeding during urgent surgery or major bleeding events. The study showed similar results for surgical and bleeding patients, with 94.3% achieving normal blood clotting after treatment.
A new study has found that a lower dose of the blood-thinning medication apixaban is as effective as the full dose in preventing recurring blood clots in patients with active cancer. Patients who received the lower dose experienced fewer bleeding complications and similar VTE recurrence rates compared to those on the standard dose.
A new study found that three months of dual antiplatelet therapy (DAPT) was better than one month for reducing heart attacks, strokes, and other adverse events without increasing bleeding risk in high-risk patients. For low-risk patients, three months of DAPT was comparable to 12 months in reducing adverse events, while being better th...
A Phase 2b trial found lorundrostat significantly reduced blood pressure in patients with uncontrolled hypertension by 7.9 mm Hg and 6.5 mm Hg compared to placebo at 12 weeks. The drug showed an acceptable side effect profile, with consistent patterns across secondary endpoints.
A study found that semaglutide significantly improved maximal walking distance in people with symptomatic peripheral artery disease (PAD) and Type 2 diabetes. Patients taking semaglutide also experienced improvements in symptoms and quality of life compared to those on a placebo.
Researchers have studied the mechanism of action of bioactive compounds from papaya, passion fruit, and medicinal plant extracts. Modified pectins extracted from these plants show potential as supplements or food ingredients to boost biological activity against colon cancer and gut microbiota.
Researchers propose GLDH as a more liver-specific biomarker for detecting liver injury, offering greater specificity than current ALT and AST tests. The test performed similarly to ALT for detecting liver injury but was not impacted by associated muscle injury.
The C-Path-led initiative brought together clinical trial sponsors, eCOA technology providers, and regulators to identify and address eCOA implementation issues. Key resources developed during the initiative include guidance on COA data collection and a more open, collaborative environment.
A UniSA-led study is trialing medication safety rounds in aged care homes to identify and address potential problems with medication use. The project aims to reduce medication-induced harm and improve residents' health and wellbeing through pharmacist-led safety rounds, adapting an existing palliative care need rounds model.
The FDA has approved cabozantinib as a standard of care treatment for patients with previously treated advanced neuroendocrine tumors. The drug showed improved efficacy in reducing tumor growth and improving patient survival compared to placebo.
Researchers at UW–Madison have discovered that the arthritis drug tofacitinib can halt brain-damaging seizures in mice, restore short-term memory, and reduce inflammation. The drug has shown promising results in preventing seizures even after treatment is stopped, offering a potential new approach for treating epilepsy.
A large study suggests that patients at high risk of heart attacks and strokes should be treated immediately with a combination of a statin and ezetimibe, rather than statins alone. This combination therapy significantly reduces the risk of death from any cause and major adverse cardiovascular events.
A natural citrus oil, when combined with a lipid formulation, may effectively relieve dry mouth in cancer patients. The new formula has demonstrated improved solubility and bioavailability compared to pure limonene.
A recent study identifies 11 natural compounds that can inhibit the SARS-CoV-2 spike protein, including caffeine, which exhibits high binding stability and excellent solubility. The discovery highlights the potential of natural products in combating COVID-19 and demonstrates the versatility of widely known compounds like caffeine.
Researchers found that digital games effective in reducing drinking, smoking, and illicit drug use among adolescents when personalized to individual players, had social components, and included content encouraging behavior change.